Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-039-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4 million
Profitability
Miscellaneous
Employees87
OptionableNot Optionable
CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions
What is CELYAD SA/ADR's stock symbol?
CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."
When is CELYAD SA/ADR's next earnings date?
What price target have analysts set for CYAD?
5 brokerages have issued 12-month target prices for CELYAD SA/ADR's stock. Their forecasts range from $44.00 to $51.00. On average, they anticipate CELYAD SA/ADR's share price to reach $47.50 in the next twelve months. This suggests a possible upside of 111.2% from the stock's current price. View Analyst Price Targets for CELYAD SA/ADR.
What is the consensus analysts' recommendation for CELYAD SA/ADR?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELYAD SA/ADR.
What are Wall Street analysts saying about CELYAD SA/ADR stock?
Here are some recent quotes from research analysts about CELYAD SA/ADR stock:
- 1. HC Wainwright analysts commented, "We base our $46 price target on probability-adjusted revenue forecasts for CYAD-01 in r/r AML and third line metastatic CRC. We use the net present value of our revenue forecast through 2026, apply a 25% POS for AML and 20% POS for CRC, a 4x price/sales multiple. We include our year-end 2018 estimated fully diluted net cash of $4.39/share (assuming €1.00 = $1.15) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x." (11/21/2018)
- 2. According to Zacks Investment Research, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. " (11/15/2018)
- 3. William Blair analysts commented, "Celyad S.A. Using the Body’s “Natural Born Killers” in Solid and Liquid Tumors; Initiating With an Outperform Rating We are initiating coverage on Celyad with an Outperform rating and $53 fair value estimate." (10/30/2018)
Has CELYAD SA/ADR been receiving favorable news coverage?
Media headlines about CYAD stock have been trending negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CELYAD SA/ADR earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of CELYAD SA/ADR's key competitors?
Some companies that are related to CELYAD SA/ADR include Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR), Epizyme (EPZM), AC Immune (ACIU), Y-mAbs Therapeutics (YMAB), Athenex (ATNX), CytomX Therapeutics (CTMX), Dynavax Technologies (DVAX), Revance Therapeutics (RVNC), Radius Health (RDUS), Principia Biopharma (PRNB) and G1 Therapeutics (GTHX).
Who are CELYAD SA/ADR's key executives?
CELYAD SA/ADR's management team includes the folowing people:
- Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)
- Dr. Christian Homsy M.D., MBA, CEO & Exec. Director (Age 61)
- Mr. Filippo Joseph Petti, Chief Financial Officer
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 44)
- Nicolas Van Hoecke, Director of Investor Relations & Communications
When did CELYAD SA/ADR IPO?
(CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
How do I buy shares of CELYAD SA/ADR?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELYAD SA/ADR's stock price today?
One share of CYAD stock can currently be purchased for approximately $22.49.
How big of a company is CELYAD SA/ADR?
CELYAD SA/ADR has a market capitalization of $215.56 million and generates $4 million in revenue each year. The company earns $-63,740,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. CELYAD SA/ADR employs 87 workers across the globe.
What is CELYAD SA/ADR's official website?
How can I contact CELYAD SA/ADR?
CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 2, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
